Literature DB >> 30546543

Cardiogenic shock induced by bisoprolol in a patient with CYP2D6 variant. A case report.

Masafumi Nakayama1,2, Koichi Fuse1, Masahito Sato1, Masaaki Okabe1, Yasushi Komatsu1,2, Akira Yamashina2, Yoshifusa Aizawa1.   

Abstract

A 66-year-old man was admitted for congestive heart failure with tachycardiac atrial fibrillation (AF). Heart failure was improved by diuretics, but control of heart rate by verapamil was insufficient, and bisoprolol was prescribed. After taking 2.5 mg of bisoprolol, he developed a general malaise followed by sinus bradycardia and shock. In addition to catecholamines, the patient was treated with intra-aortic balloon pumping and a pacemaker. With intensive therapy, the general condition was improved, and acute elevation of liver enzymes after bisoprolol was normalized by the 17th hospital day. The blood sample taken 30 h after the intake of bisoprolol showed abnormally high levels. Although the patient was CYP2D6*10 heterozygote, the precise mechanism for excess accumulation of bisoprolol and refractory shock remains unknown. <Learning objective: Bisoprolol has been used for heart failure, but it may need caution to avoid hemodynamic deterioration. In our case, refractory shock and acute liver injury were induced by bisoprolol. The blood concentration was excessively high. The patient was CYP2D6*10 heterozygote, but the precise mechanism and shock are to be studied.>.

Entities:  

Keywords:  Bisoprolol; CYP2D6 polymorphism; Cardiogenic shock

Year:  2015        PMID: 30546543      PMCID: PMC6279976          DOI: 10.1016/j.jccase.2014.12.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

1.  Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Akihiko Igawa; Hiroshi Inoue; Chihiro Takesono; Katsutoshi Tahara; Yukiya Hashimoto
Journal:  Biol Pharm Bull       Date:  2005-05       Impact factor: 2.233

Review 2.  Pharmacogenetics, drug-metabolizing enzymes, and clinical practice.

Authors:  Sharon J Gardiner; Evan J Begg
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).

Authors:  Kanako Sakuyama; Takamitsu Sasaki; Shuta Ujiie; Kanako Obata; Michinao Mizugaki; Masaaki Ishikawa; Masahiro Hiratsuka
Journal:  Drug Metab Dispos       Date:  2008-09-10       Impact factor: 3.922

4.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.

Authors:  Michael Böhm; Karl Swedberg; Michel Komajda; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

5.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

6.  Pharmacokinetics and metabolism of bisoprolol enantiomers in humans.

Authors:  Y Horikiri; T Suzuki; M Mizobe
Journal:  J Pharm Sci       Date:  1998-03       Impact factor: 3.534

Review 7.  Rate control in atrial fibrillation: looking beyond the average heart rate.

Authors:  Kamran Ahmad; Paul Dorian
Journal:  Curr Opin Cardiol       Date:  2006-03       Impact factor: 2.161

8.  Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy.

Authors:  Tadashi Fujino; Takeshi Yamashita; Shinya Suzuki; Hiroaki Sugiyma; Koichi Sagara; Hitoshi Sawada; Tadanori Aizawa; Masaki Igarashi; Junichi Yamazaki
Journal:  Circ J       Date:  2007-06       Impact factor: 2.993

Review 9.  Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.

Authors:  Genevieve Flannery; Rosie Gehrig-Mills; Baki Billah; Henry Krum
Journal:  Am J Cardiol       Date:  2008-02-21       Impact factor: 2.778

10.  Balanced pharmacokinetics and metabolism of bisoprolol.

Authors:  G Leopold
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.